Michigan Clinical Trials

A listing of Michigan clinical trials actively recruiting patient volunteers.

Making the decision to participate in a clinical trial is a very personal one. Some individuals do it because they have run out of options and want to try a new experimental treatment in the hope it might help their condition, while others do it because they want to do their part helping the clinical community move forward and potentially help cure many people down the line. For individuals looking to participate, there are a wide array of clinical trials in Michigan looking for participants who can commit to seeing the trials through. The biggest city of Michigan is Detroit, "The Motor City" that was central to America's auto industry for decades. Lansing is the capital, while Ann Arbor and Grand Rapids round out the list with some of the most beautiful views of any urban area in America. Michigan boasts the longest freshwater coastline of any U.S. state, adding to its reputation for outdoor recreation. Today's Michigan is increasingly building businesses in professional services, health, and education. Medical care has kept up with the times, with the University of Michigan Hospitals and Health Centers blazing the trail toward world class community health.

Search by Name
Search
Filter by Condition
2346 trials found

International Registry for Severe Chronic Neutropenia

NCT00004342

OBJECTIVES: I. Document the clinical course of severe chronic neutropenia (SCN). II. Monitor and assess long term safety of primary treatment in SCN patients in the United States, Canada, Europe, and Australia. III. Study the incidence and outcome of adverse events such as osteoporosis, splenomegaly, cytogenetic abnormalities, myelodysplastic syndrome, and leukemia. IV. Evaluate growth and development and hematologic parameters. V. Monitor for clinically significant changes in primary treatme ...

Conditions: Neutropenia

Follow-up Visit of High Risk Infants

NCT00009633

The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may ...

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature

Generic Database of Very Low Birth Weight Infants

NCT00063063

The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature

Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

NCT00082745

This clinical trial studies cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, avascular necrosis, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications.

Conditions: Childhood Malignant Neoplasm

Mucopolysaccharidosis I (MPS I) Registry

NCT00144794

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities. The objectives of the Registry are: To evaluate the long- ...

Conditions: Mucopolysaccharidosis I (MPS I)

Fabry Disease Registry & Pregnancy Sub-registry

NCT00196742

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary objectives of the Registry are: To enhance the understanding of the variability, progression, and natural history of Fab ...

Conditions: Fabry Disease

Pompe Disease Registry Protocol

NCT00231400

The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes. The objectives of the Registry are: To enhance understanding of the ...

Conditions: Glycogen Storage Disease Type II, Pompe Disease

Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

NCT00246857

This study will determine the biochemical and genetic causes of inherited immune diseases affecting lymphocyte homeostasis. Lymphocytes are a type of white blood cell that fights infections. Normally, the body keeps a precise balance in which lymphocyte growth is matched by lymphocyte death. People with constantly enlarged lymph nodes or spleen, along with autoimmune disease, immunodeficiency, lymphoma, or other immune problems affecting lymphocytes may have an abnormality of the immune system i ...

Conditions: Primary Immune Deficiency

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

NCT00271180

The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia

DILIN's Prospective Study

NCT00345930

The purpose of this study is to identify individuals who have suffered a liver injury arising as an idiosyncratic reaction to a prescription drug or a complementary and alternative medicine. Recently added acute cases enrollment that meets criteria to the protocol. Also added Fibroscans to the protocol that will be completed at baseline and follow-up on chronic subjects.

Conditions: Liver Diseases

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

NCT00358943

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives of the Registry are: To enhance understanding of the variability, progression, identification, and natural h ...

Conditions: Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease

Drug-Induced Liver Injury (DILN)Network Retrospective

NCT00360646

The purpose of this study is to establish retrospectively a nationwide registry of patients who have suffered drug-induced liver injury (DILI), and to collect, immortalize and store serum, DNA, and lymphocytes from these patients. ILIAD will serve as a resource for subsequent mechanistic investigations into the basis of severe idiosyncratic DILI. The primary goal of the ILIAD protocol is to create: (a) a clinical database consisting of individuals who have experienced severe DILI caused by four ...

Conditions: Drug Induced Liver Injury

Clinical trials vary in time; in total a single clinical trial may take up to 15 years to complete, and some longitudinal studies ask the participant to stay in touch for follow up questions for a few years after their participation in the study is finished. Depending on the goal and the design of a clinical trial, volunteers may be asked to stay on site for a set amount of nights; this happens because the researchers might want to monitor the participant's at different hours of the day or night. Some clinical research is also setup to compensate individuals, and paid clinical trials are not uncommon.

In Michigan, the University of Michigan division of research has one of the largest clinical trial and research centers in the state, where interested volunteers can enroll in studies for healthy or non-healthy individuals. The Barbara Ann Karmanos cancer institute in Detroit, Michigan also offers clinical trials for many types of cancers for both healthy and non-healthy individuals.

Volunteers who decide to participate in a clinical trial may be compensated for their time and travel expenses during their participation in the study. The compensation will vary depending on the type of study and level of participation required from the volunteer, but paid clinical trials in Michigan are very common.

Participating in a clinical trial is always completely voluntary. This means that nobody, regardless of their condition can be forced to participate nor can they be forced to continue participating in a trial if they wish to withdraw from the study. Non-healthy individuals who decide to enroll in a clinical trial after a suggestion from their doctor or to try an experimental treatment for their condition will never be denied care if they decide to drop out of the study.